Recruiting | Phase Not Applicable
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial)
To determine if having patients report their symptoms of cancer treatment electronically on weekly basis will benefit patients more than patient report symptoms at appointments, and gather perspectives on reporting symptoms online or over the phone from patients and staff.
Patients will use an online system or automated phone system to report their symptoms on a weekly basis for up to 12 months or until treatment is discontinued
- Quality of Life questionnaires
After completion of study therapy, patients are followed up on at 18 months and 24 months from enrollment
Key Participation Requirements:
Male or Female
21 years and older
Patients with advanced or metastatic cancer of ANY type except leukemia or indolent lymphoma.
Patients must be receiving outpatient cancer treatment that is being used to control a cancer or reduce its symptoms but not cure it, including chemotherapy, targeted therapy, or immunotherapy.
Patients being treated with curative intent are not eligible
Patients receiving hormonal therapy only are not eligible
Patients can be at ANY point of their treatment.
Patients must be able to understand English, Spanish, or Mandarin Chinese.
Patients must not be participating in any other clinical trial
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Methodist Health System Trial Code:
For more information, visit the U.S. National Library of Medicine clinical trial database.